A Prospective Real World Study of Rimegepant in the Treatment of Migraine
NCT ID: NCT05709106
Last Updated: 2024-07-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2023-01-11
2025-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer are:
* \[question 1\] the effectiveness and safety of Rimegepant in the acute treatment of migraine
* \[question 2\] the effectiveness and safety of Rimegepant in the long-term treatment of migraine.
1. Participants will be asked to take Rimegepant when they need to treat or prevent a migraine attack.
2. Participants will be asked to record the efficacy data at 0.5, 1, 2, 24, 48h post dose and report any AE to evaluate the effectiveness and safety of Rimegepant in the acute treatment of migraine
3. Participants will be asked to track monthly migraine days and the use of Rimegepant, finish 2 PROs during the follow-ups, report any AE to evaluate the effectiveness and safety of Rimegepant in the long-term treatment of migraine.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Real-world Study of Rimegepant Treatment in Female Migraine Patients of China
NCT06728345
A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.
NCT06467370
A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
NCT05810038
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
NCT05217927
A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area
NCT06221267
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rimegepant treatment group
this group would use Rimegepant 75mg ODT, use it when needed for 1year
Rimegepant 75 MG
Migraine patients would take Rimegepant 75 MG to treat or prevent a migraine attack and patients would be followed up for 1 year
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rimegepant 75 MG
Migraine patients would take Rimegepant 75 MG to treat or prevent a migraine attack and patients would be followed up for 1 year
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Rimegepant is prescribed by the physician for the treatment of patients with migraine.
* Patients signed written informed consent.
* Male and Female subjects ≥ 18 years and older
* Patients is not participated in other concurrent interventional clinical studies.
Exclusion Criteria
* Pregnant patients
* Lactating female patients
* Patients who are highly dependent on medical care.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jun Liu
Role: PRINCIPAL_INVESTIGATOR
Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine
Boao, Hainan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Yang Z, Wang X, Niu M, Wei Q, Zhong H, Li X, Yuan W, Xu W, Zhu S, Yu S, Liu J, Yan J, Kang W, Huang P. First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients. J Headache Pain. 2024 Sep 27;25(1):160. doi: 10.1186/s10194-024-01873-5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ky2022005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.